NCT03564275Active, not recruiting
Proton Boost in Prostate Cancer
Assessing the Effectiveness of Photon Therapy With a Proton Therapy Boost in the Treatment of Prostate Cancer as Compared to Photon Therapy Alone
Source: ClinicalTrials.gov · Last updated 31 May 2025
Brief summary (registry, in English)
This study uses photon radiation with a proton boost to treat prostate cancer. The purpose of this study is to determine if proton therapy as a boost following photon intensity modulated radiation therapy (IMRT) produces decreased toxicity as compared to conventional photon IMRT alone in the treatment of prostate cancer. Our secondary objective is to determine the effectiveness of this treatment regimen. Effectiveness will be determined by length of time to progression or recurrence of disease and overall survival. Patients on this study will be treated with a course of photon radiation therapy followed by a boost course of proton radiation.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 18 May 2018
- Start date
- 16 Apr 2018
- Primary completion date
- Apr 2033
- Lead sponsor
- University of Cincinnati
- Diseases
- Prostate cancer
- NCT number
- NCT03564275
What you commit to
- Study type: Interventional
- Participants enrolled: 10
- From 16 Apr 2018 to the primary completion date, Apr 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or historical use of androgen deprivation therapy
Other illness
- Diagnosis of high risk prostate cancer (T3 or higher, Gleason \>7 and/or PSA \>20)
- Previous cancer excluding non-melanoma skin cancer
- History of prostatectomy
- History of brachytherapy for prostate cancer
Age
- \< 18 years of age
- Life expectancy \<10 yrs
Other
- Nodal positivity
- Physically or mentally incapable of signing the consent form of their own volition
Who the study is looking for
- ≥18 years of age
- Diagnosis of low risk prostate cancer (T1c-T2a, Gleason 6, Prostate Specific Antigen (PSA) \<10) -OR-
- Diagnosis of intermediate risk prostate cancer (T1c-T2c, Gleason 7 and/or PSA 10- 20)
- Life expectancy \>10 yrs
- Physically and mentally capable of signing the consent form of their own volition
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Cincinnati Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.